drugset / Trial / NCT01310738

Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil

NCT01310738

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is aimed to compare the efficacy and safety of medications currently used in Brazil for treatment of visceral leishmaniasis. The investigators will compare the effects of meglumine antimoniate, two formulations of amphotericin B: deoxycholate and liposomal, and a combination of meglumine plus the liposomal amphotericin B formulation. The study is designed to demonstrate the difference in efficacy measured as cure rate at six months after treatment and the safety profile based on the adverse event rate observed with each intervention.

Timeline

Start
2011-02
Primary completion
2014-10
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 3 mg/kg Intravenous
Subject Amphotericin B Unknown 10 mg/kg Intravenous
Subject Meglumine antimonate Other / unclassified 20 mg/kg Intravenous
Subject amphotericin B deoxycholate Unknown 1 mg/kg Intravenous